Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Jul 02, 2022 3:50pm
351 Views
Post# 34797554

Because of a lack of better treatments...

Because of a lack of better treatments...Question?
Why keytruda that has a a very low 18%CR and many serious side effects, was accepted by the FDA for Bladder Cancer patients.

In this article dated Jan.10, 2020..
https://gr-cis.com/2020/01/10/mercks-keytruda-approved-for-high-risk-bladder-cancer/ .
Paragraph 5,
Merck said" Keytruda will be a new clinical option for a patients population that previously had limited FDA- Approved therapies available".

Can you believe this... Keytruda with its very low CR% and serious side effects was approved by the FDA for Bladder cancer, because of a lack of better treatments.

TLT time is coming.





<< Previous
Bullboard Posts
Next >>